MIM
ACGN

MetLife Investment Management’s Aceragen Inc ACGN Stock Holding History

MetLife Investment Management’s Portfolio ACGN Stock Details ACGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-540
Closed -$135K – 2234
2018
Q1 		$135K Hold
540
– – ﹤0.01% 2086
2017
Q4 		$155K Buy
+540
New +$154K ﹤0.01% 2053

Other funds holding ACGN

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's ACGN Position: Q2 2018 in Review

MetLife Investment Management sold out of Aceragen Inc (ACGN) in Q2 2018, closing a stake of 540 shares — an estimated $135K sold.

MetLife Investment Management first reported a position in ACGN in Q4 2017 and held it in 2 quarters. The position peaked at $155K in Q4 2017. 93 funds tracked by Wall St. Rank hold ACGN as of Q2 2018.

  • MetLife Investment Management reported no remaining Aceragen Inc position as of Q2 2018 after selling out during the quarter.
  • MetLife Investment Management sold 540 Aceragen Inc shares in Q2 2018, an estimated $135K.
  • MetLife Investment Management first reported a position in Aceragen Inc in Q4 2017 and held it in 2 quarters.
  • MetLife Investment Management's Aceragen Inc position peaked at $155K in Q4 2017.
  • 93 funds tracked by Wall St. Rank held Aceragen Inc as of Q2 2018.

Based on MetLife Investment Management's 13F filing for Q2 2018, filed 15 Aug 2018.